ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 872

Interferon-α and Angiogenic Dysregulation in Pregnant Lupus Patients Destined for Preeclampsia

Danieli Andrade1, Mimi Kim2, Luz P. Blanco3, S. Ananth Karumanchi4, Gloria Koo5, Patricia M. Redecha6, Kyriakos A. Kirou1, Angela M. Alvarez7, Melissa J. Mulla7, Mary K. Crow8, Vikki Abrahams7, Mariana J. Kaplan3 and Jane E. Salmon9, 1Hospital for Special Surgery, New York, NY, 2Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, 3Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 4Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 5Autoimmunity & Inflammation, Hospital for Special Surgery, New York, NY, 6Rheumatology Research, Hospital for Special Surgery, New York, NY, 7Yale School of Medicine, New Haven, CT, 8Department of Medicine, Hospital for Special Surgery, New York, NY, 9Rheumatology, Hospital for Special Surgery, New York, NY

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: interferons, pregnancy and vasculogenesis, SLE

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis I: Pathways of Inflammation/Injury

Session Type: Abstract Submissions (ACR)

Background/Purpose: Pregnant patients with SLE are at increased risk of placental insufficiency and preeclampsia, disorders associated with angiogenic factor imbalance. IFN-α, a critical element in SLE pathogenesis, is a potent antiangiogenic factor.  In a case-control longitudinal study of lupus pregnancies from PROMISSE (Predictors of Pregnancy Outcome: Biomarkers In Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus), we investigated whether elevated IFN-α early in pregnancy might be associated with poor pregnancy outcomes.

Methods: Each of 28 SLE patients with poor pregnancy outcome was matched to an SLE patient with an uncomplicated pregnancy and to a pregnant healthy control. Serum samples obtained monthly through pregnancy were assayed for IFN-α activity using a reporter cell assay, and for antiangiogenic factor, sFlt1, and proangiogenic factor, placenta growth factor (PlGF).  Human umbilical vein endothelial cells (HUVEC) were cultured in the presence of IFN-α and/or sFlt1, and gene expression assessed by q-RT PCR. The effect of IFN-α and sFlt1 on endothelial-trophoblast interactions was assessed in an in vitro model of spiral artery transformation in which the capacity of human first trimester extravillous trophoblasts to stabilize endometrial endothelial cell tube structures is measured.

Results: Compared to SLE patients with uncomplicated pregnancies, those with preeclampsia had increased IFN-α before clinical symptoms. Non-autoimmune patients destined for preeclampsia did not have increased IFN-α. In SLE patients with low IFN-α, marked angiogenic imbalance (higher sFlt1, lower PlGF and higher sFlt1/PLGF ratios) precedes maternal manifestations of preeclampsia, whereas in SLE with high IFN-α, preeclampsia occurs without evidence of systemic angiogenic imbalance.  To investigate this result, we treated HUVEC with exogenous sFlt1 and IFN-α.  Treatment with sFlt1 induced the expression of sFlt1 mRNA, and IFN-α dramatically amplified the endothelial response to sFlt1, leading to a local positive feedback loop.  Furthermore, in an in vitro  model of spiral artery transformation, only IFN-α and sFlt1 together disrupted the ability of trophoblast cells to remodel endothelial tube structures.

Conclusion: Our studies identify a new mechanism by which IFN-α induces an antiangiogenic milieu in the vasculature leading to inadequate spiral artery remodeling and poor placentation early in pregnancy and maternal endothelial dysfunction presenting as preeclampsia later in pregnancy. They suggest that elevated IFN-α may contribute to the pathogenesis of preeclampsia in some pregnant women with SLE.


Disclosure:

D. Andrade,
None;

M. Kim,
None;

L. P. Blanco,
None;

S. A. Karumanchi,

Aggamin Pharmaceuticals,

1,

Thermofisher,

2,

Siemens Diagnostics,

5,

Beth Israel Deaconness Medical Center,

7;

G. Koo,
None;

P. M. Redecha,
None;

K. A. Kirou,
None;

A. M. Alvarez,
None;

M. J. Mulla,
None;

M. K. Crow,
None;

V. Abrahams,
None;

M. J. Kaplan,
None;

J. E. Salmon,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interferon-%ce%b1-and-angiogenic-dysregulation-in-pregnant-lupus-patients-destined-for-preeclampsia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology